Gyre Therapeutics Inc.
GYRE | NASDAQ
$4.55
-$1.86 (-29.02%)
At close: Oct 30, 2026, 4:00 PM ET
$5.02
+$0.47 (+10.33%)
Pre-market:
Nov 2, 2026, 6:00 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 116.59M | 105.76M | 113.45M | 102.29M | 7.34M | 20.95M |
Cost of Revenue | 5.42M | 3.88M | 4.64M | 4.79M | 7.67M | 9.16M |
Gross Profit | 111.17M | 101.87M | 108.81M | 97.5M | -332K | 11.79M |
Operating Income | 11.49M | 16.23M | -67.23M | 9.2M | -83.73M | -57.37M |
Interest Income | 1.75M | 1.55M | 1.04M | 726K | 39K | 561K |
Pretax Income | 14.44M | 23.22M | -76.97M | 9.41M | -87.93M | -56.24M |
Net Income | 5.03M | 12.09M | -92.93M | 2.3M | -87.93M | -55.54M |
Selling & General & Admin | 85.98M | 73.62M | 75.82M | 71.61M | 18.82M | 16.18M |
Research & Development | 13.7M | 12.02M | 13.78M | 16.69M | 64.57M | 52.98M |
Other Expenses | n/a | 66K | 86.44M | n/a | n/a | n/a |
Operating Expenses | 99.68M | 85.71M | 176.04M | 88.29M | 83.39M | 69.16M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | 65.18M | 57.51M | 61.16M | 54.24M | n/a | n/a |
Cost & Expenses | 105.1M | 89.59M | 180.68M | 93.09M | 91.06M | 78.32M |
Income Tax Expense | 4.56M | 5.32M | 8.52M | 5.1M | n/a | -699K |
Shares Outstanding (Basic) | 89.34M | 85.09M | 65.83M | 75.69M | 30.64M | 19.18M |
Shares Outstanding (Diluted) | 103.18M | 102.29M | 65.83M | 75.69M | 30.64M | 19.18M |
EPS (Basic) | 0.06 | 0.14 | -1.41 | 0.03 | -2.87 | -2.93 |
EPS (Diluted) | 0.02 | 0.05 | -1.41 | 0.03 | -2.87 | -2.93 |
EBITDA | 16.96M | 17.82M | 20.33M | 10.54M | -87.64M | -56.1M |
EBIT | 14.44M | 16.23M | 19.21M | 9.41M | -87.93M | -56.24M |
Depreciation & Amortization | 2.52M | 1.59M | 1.11M | 1.13M | 290K | 138K |
Add to Watchlist
Select watchlists to add or remove GYRE